Serial plasma cell-free DNA genotyping analyses of 106 ER+ breast cancer patients over the course of treatment with palbociclib and fulvestrant were analyzed, and patients who developed KRAS mutations over time became resistant to palbociclib [57]. Here, KRAS is linked to breast carcinoma.